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Introduction
NK cell deficiency (NKD) is an inborn or primary immunodefi-
ciency causing susceptibility to severe and often fatal viral infec-
tion and malignancy (1–5). NKD can be classified as classical, aris-
ing from profound or complete absence of the NK cell population 
or major subsets of peripheral NK cells, or functional, arising from 
impaired NK cell function with normal peripheral NK cell counts 
(5, 6). There are presently 2 genetically defined causes of classical 
(MCM4, GATA2) and 1 of functional NKD (FCGR3A) (2–4, 7–9).
Human NK cell development results in generation of distinct 
phenotypic and functional subsets found in peripheral blood: 
namely the CD56bright and CD56dim subsets. While identified pri-
marily by the density of CD56 on the cell surface, these subsets 
include the coordinated expression of cell surface and intracellu-
lar markers that reflect each subset’s unique function. CD56bright 
NK cells are considered immunomodulatory and are described 
phenotypically as CD16−/loCD57−perforinlo, CD117+, CD62Lhi, 
and CD94/NKG2A+. While they constitute the minority of NK 
cells in peripheral blood, they represent the dominant population 
in secondary lymphoid tissue (10, 11). CD56dim NK cells, which 
constitute more than 90% of peripheral blood NKs, are CD56dim 
CD16hiperforinhiCD57+/− killer-cell immunoglobulin-like receptor+ 
(KIR+), and are the primary mediators of NK cell–mediated cyto-
toxicity. The relationship between the subsets is not complete-
ly understood, but both in vivo and ex vivo evidence in humans 
Human NK cell deficiencies are rare yet result in severe and often fatal disease, particularly as a result of viral susceptibility. 
NK cells develop from hematopoietic stem cells, and few monogenic errors that specifically interrupt NK cell development 
have been reported. Here we have described biallelic mutations in IRF8, which encodes an interferon regulatory factor, as a 
cause of familial NK cell deficiency that results in fatal and severe viral disease. Compound heterozygous or homozygous 
mutations in IRF8 in 3 unrelated families resulted in a paucity of mature CD56dim NK cells and an increase in the frequency 
of the immature CD56bright NK cells, and this impairment in terminal maturation was also observed in Irf8–/–, but not Irf8+/–, 
mice. We then determined that impaired maturation was NK cell intrinsic, and gene expression analysis of human NK cell 
developmental subsets showed that multiple genes were dysregulated by IRF8 mutation. The phenotype was accompanied 
by deficient NK cell function and was stable over time. Together, these data indicate that human NK cells require IRF8 for 
development and functional maturation and that dysregulation of this function results in severe human disease, thereby 
emphasizing a critical role for NK cells in human antiviral defense.
Biallelic mutations in IRF8 impair human NK cell 
maturation and function
Emily M. Mace,1,2,3 Venetia Bigley,4 Justin T. Gunesch,1,3 Ivan K. Chinn,1,2,5 Laura S. Angelo,1 Matthew A. Care,6 Sheetal Maisuria,7 
Michael D. Keller,8 Sumihito Togi,9 Levi B. Watkin,1 David F. LaRosa,10 Shalini N. Jhangiani,5 Donna M. Muzny,5  
Asbjørg Stray-Pedersen,5,11 Zeynep Coban Akdemir,5,11 Jansen B. Smith,1 Mayra Hernández-Sanabria,1 Duy T. Le,1  
Graham D. Hogg,1 Tram N. Cao,1 Aharon G. Freud,12,13 Eva P. Szymanski,14 Sinisa Savic,7 Matthew Collin,4 Andrew J. Cant,15  
Richard A. Gibbs,5 Steven M. Holland,14 Michael A. Caligiuri,13,16 Keiko Ozato,9 Silke Paust,1,2,17 Gina M. Doody,6  
James R. Lupski2,5,11, and Jordan S. Orange1,2,3,17
1Center for Human Immunobiology, Texas Children’s Hospital, Houston, Texas, USA. 2Department of Pediatrics, 3Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA. 
4Institute of Cellular Medicine, University of Newcastle, Newcastle upon Tyne, England, United Kingdom. 5Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA. 6Section of 
Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom. 7Department of Clinical Immunology and Allergy, St James’s University Hospital, Leeds, 
United Kingdom. 8Division of Allergy and Immunology, Center for Cancer and Immunology Research, Children’s National Health System, Washington, DC, USA. 9Laboratory of Molecular Growth Regulation, 
Program in Genomics of Differentiation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA. 10Department of Pediatrics, University of 
Pennsylvania School of Medicine, Children’s Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania, USA. 11Department of Molecular and Human Genetics, Baylor College of Medicine, 
Houston, Texas, USA. 12Division of Hematopathology, Department of Pathology, The Ohio State University, Columbus, Ohio, USA. 13The Ohio State University Comprehensive Cancer Center, The James Cancer 
Hospital and Solove Research Center, Columbus, Ohio, USA. 14Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA..15Department of Paediatric Immunology and Bone Marrow 
Transplantation, Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom. 16Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.  
17Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA
Conflict of interest: J.R.Lupski has stock ownership in 23andMe, is a paid consultant 
for Regeneron Pharmaceuticals, has stock options in Lasergen, Inc. is a member of the 
Scientific Advisory Board of Baylor Genetics, and is a co-inventor on multiple United 
States and European patents related to molecular diagnostics for inherited neuropathies, 
eye diseases, and bacterial genomic fingerprinting (5294533; 5306616; 5523217; 5599920; 
5667968; 5780223; 6132954; 6713300; 7141420; 7189511; 7192579; 7273698; 7537899; 
8129353; 9365899; 0424473; 0610396; 0989805). The Department of Molecular and 
Human Genetics at Baylor College of Medicine derives revenue from the chromosomal  
microarray analysis (CMA) and clinical exome sequencing offered in Baylor Genetics 
(BMGL: http://www.bmgl.com/BMGL/Default.aspx). 
Submitted: December 30, 2015; Accepted: October 18, 2016.
Reference information: J Clin Invest. doi:10.1172/JCI86276.
Downloaded from http://www.jci.org on December  1, 2016.   https://doi.org/10.1172/JCI86276
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 jci.org
ciency leading to specific loss of the CD11c+CD1c+ circulating DC 
subset (19). K108E mutations of IRF8 have an even more profound 
impact, leading to the loss of DCs as well as monocytes (19).
Before recent advances in genomic sequencing technology, 
NKD was reported in a number of pediatric cases. Perhaps the 
most renowned was an isolated case of NKD and viral suscepti-
bility ultimately proven as resulting from a GATA2 mutation (4, 
22). The original NKD case, however, was reported in 1982 as a 
familial, non–X-linked susceptibility to EBV infection that led to 
the death of 2 affected siblings and ongoing illness in a third (1). 
Here we report that biallelic mutations in IRF8 cause intrinsic 
NKD with decreased NK cell number, decreased frequency of 
the CD56dim subset, and accompanying susceptibility to viral and 
mycobacterial infection. In doing so we define and characterize 
IRF8 mutations in this original, unsolved family with NKD and 
identify NKD in 2 unrelated patients with biallelic IRF8 mutations. 
These data identify IRF8 as a critical regulator of NK cell terminal 
maturation and define a novel cause of a rare human inborn NK 
cell developmental defect.
Results
Patients and clinical history. The index case proband (II.2) present-
ed with a history of sinopulmonary infections during childhood 
and severe infectious mononucleosis at age 22 years requiring pro-
longed hospitalization (1). Born to non-consanguineous parents, 
his brother (II.6) died at age 16 years of multiple organ failure fol-
lowing severe EBV mononucleosis, and his sister (II.5) died at age 
38 years due to progressive pulmonary disease. She also had pro-
longed hospitalization at age 17 years for severe EBV mononucleo-
sis. Both siblings had lymphadenopathy and bronchiectasis begin-
ning in childhood. Notably, the 3 siblings’ EBV-related illnesses 
occurred in separate calendar years. A fourth sibling (brother, II.3) 
had EBV mononucleosis at age 21 years at the same time as the 
proband, but had a typical course of illness and did not require 
hospitalization. The unusual nature of disease and clinical pre-
suggests that the CD56bright subset is a developmental precursor 
of CD56dim, and it is hypothesized that secondary lymphoid tissue 
serves as a site of NK cell terminal differentiation that is required 
for acquisition of cytotoxic function (12–15).
Specific loss of NK cells or NK cell subsets as occurs in classical 
NKD is rare but has been reported. Homozygous MCM4 mutation 
causes adrenal insufficiency, decreased numbers of circulating NK 
cells, and impaired terminal maturation, likely as a result of chro-
mosomal aberrations and impaired proliferation of the CD56bright 
subset (2, 3). These patients show distinctive loss of the CD56dim 
subset and correlative relative increase in the CD56bright subset (2). 
In contrast, GATA2 mutations result in specific loss of CD56bright 
NK cells and decreased frequency of NK cells overall in circulat-
ing blood. While GATA2 patients have CD56dim NK cells that vary 
in number, they are largely nonfunctional, and affected patients 
develop severe herpesvirus and papillomavirus infections (4). NKD 
has also been reported in 1 isolated case of a child with a mutation 
in RTEL1, encoding regulator of telomere elongation helicase, 
although NK cell subsets were not examined in this case (16, 17).
Interferon regulatory factor 8 (IRF8; also known as interferon 
consensus binding protein, ICSBP) is a member of the IRF family 
of transcription factors that help shape the inflammatory response, 
particularly to viral infections. These transcription factors are also 
becoming increasingly recognized for their roles in human hema-
topoiesis through rare, naturally occurring germline mutations.
Mutations of IRF8 in mice and humans cause cellular defi-
ciency ranging from severe defects of monocyte and DC produc-
tion with marked myeloproliferation to more subtle alterations of 
specific DC subsets with normal leukocyte counts (18–20). Gene 
dosage and mutation site–specific effects have been observed, sug-
gesting that the level of IRF8 activity is critical to normal immune 
cell development and function. In addition to developmental aber-
rations, mature cell function is affected as exemplified by defects 
in macrophage function (21). In humans, heterozygous IRF8 T80A 
mutations have been identified as a cause of primary immunodefi-
Table 1. NK characteristics and clinical phenotypes of subjects with IRF8 mutations
Relationship Mutation/ExAC frequency NK phenotype NK number NK function Age (yr) Clinical phenotype
Proband A201V/P224L ↑CD56bright ↓44 (159–432); ALC: 2,994 
(900–3,245)
↓ 46–59 EBV, pneumonia
Sister of proband Unknown/P224L ND ↓ (see ref. 1) ↓ (see ref. 1) NA EBV, pneumonia (deceased)
Brother of proband A201V/WT (0.002515) Normal Normal Normal 59 None
Mother of proband P224L/WT (0.00004469) Normal Normal Normal ND None
Son of proband P224L/WT (0.00004469) Normal Normal Normal 32 None
Son of proband P224L/WT (0.00004469) Normal Normal Normal 29 None
Daughter of proband A201V/WT (0.002515) Normal Normal Normal ND None
Unrelated A201V/WT (0.002515) Normal Normal Normal 68 PNTM
Unrelated T96M/WT (0.0005608) Normal Normal Normal 62 PNTM
Unrelated G139S/WT (0.000593) Normal Normal Normal 64 PNTM
Unrelated A179V/WT (not found) Normal Normal Normal 57 Disseminated NTM
Unrelated K108E/K108E (not found) ↑CD56bright (see ref. 77) ND <1 Disseminated BCG disease 
(ref. 77)
Unrelated R83C/R291Q (not found) ↑CD56bright ↓ ND ND Recurrent respiratory infection
ALC, absolute lymphocyte count; BCG, bacille Calmette-Guérin; ND, not done; NTM, nontuberculous mycobacterial disease; PNTM, pulmonary 
nontuberculous mycobacterial disease.
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samples (proband, 105X; mother, 124X; brother, 116X; son, 114X; 
fraternal nephew, 90X). The exome data suggested disease-relat-
ed segregation of mutations in IRF8 (NM_002163:c.602C>T, 39 
variant reads of 112 total in the proband; NM_002163:c.671C>T, 44 
variant of 72 total proband reads) predicted by conceptual transla-
tion to result in amino acid changes p.A201V and p.P224L, respec-
tively. Of those mutations predicted to be damaging by SIFT, Poly-
Phen, LRT, and MutationTaster algorithms, few aside from IRF8 
were expressed highly in immune cells, particularly NK cells (see 
Supplemental Table 1 for list of variants identified by whole exome 
sequencing; supplemental material available online with this arti-
cle; doi:10.1172/JCI86276DS1). Sanger sequencing of IRF8 in the 
proband’s sons and daughter confirmed the presence of both alleles 
in his children and the absence of either variant in his wife (Figure 
1B and Supplemental Figure 1). The P224L variant was present in 
his mother, and the A201V variant was present in a surviving broth-
er. Therefore, IRF8 mutations were confirmed with familial segre-
gation in accordance with Mendelian expectations. In addition, the 
P224L mutation was confirmed from paraffin-embedded tissue 
sentation in the proband prompted immunological evaluation and 
was described as a novel, non–X-linked immune deficiency lead-
ing to susceptibility to EBV disease associated with a deficiency of 
NK cell cytotoxicity (1). Since the original description, the patient 
has continued to have fairly regular, recurrent episodes of sinusitis 
and has mucosal changes consistent with recurrent and chronic 
disease as well as presumably respiratory viral infections. He has 
no evidence of bronchiectasis or lymphadenopathy. T cell and B 
cell counts have been consistently normal, and immunoglobulins 
are present in normal quantities and quality. His surviving broth-
er (II.3), mother (I.1), children (III.1–3), and nephew (III.4) have 
unremarkable medical histories. Other unrelated patients are 
summarized in Table 1.
Genetics. The 1982 description of the proband’s family is with-
out follow-up until now and did not include any genetic or genom-
ic analysis. Thus, whole exome sequencing of genomic DNA was 
performed using blood samples collected from the proband; his 
son, mother, and surviving brother; and the son of the brother (Fig-
ure 1A). Excellent average per-base coverage was observed for all 
Figure 1. Linkage analysis of IRF8 compound heterozygous mutations in familial NKD and genetic confirmation of mutation. (A) Pedigree of affected 
family. Roman numerals indicate generations. Arrow points to proband. Shown are amino acid variants in IRF8 as detected by whole exome sequencing. 
Asterisk indicates variant confirmed by Sanger sequencing. (B) Confirmation of proband’s IRF8 variants by Sanger sequencing. (C) Schematic of human 
IRF8 showing affected residues found within the IRF association domain. (D) Protein expression of IRF8 in EBV-transformed patient B cell line (maroon, 
solid line) relative to normal control (blue, dashed line). Isotype control is shown in black. Shown is 1 representative experiment from 3 independent 
repeats. (E) Western blot of IRF8 (48 kDa) in healthy donor (HD) or patient (Pt) lymphoblastoid cell lines with actin (42 kDa) as a loading control. Shown 
is 1 representative experiment from 3 independent repeats. (F) Nuclear localization of IRF8 in patient (Pt) or control (Ctrl) B cell lines or healthy donor 
NK cells. Cells were fixed and stained for IRF8 (eFluor 710, red) followed by counterstaining with DAPI (blue). Scale bar: 10 μm. Shown is 1 representative 
experiment from 3 independent repeats.
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Evaluation of the patient’s protein expression by flow cytom-
etry in lymphoblastoid cell lines showed normal levels of expres-
sion (Figure 1D), and Western blot analysis of IRF8 from patient 
EBV-transformed B cell lines confirmed protein expression at the 
expected molecular weight of full-length protein, as did healthy 
donor (Figure 1E; see complete unedited blots in the supplemental 
material). The only previously reported homozygous mutation in 
IRF8, K108E, was shown to impair nuclear translocation of IRF8 in 
transfected cells (21). To determine whether the novel compound 
heterozygous alleles found in our proband prevent the nuclear 
recruitment of IRF8, we evaluated the patient B cell line by imag-
from the patient’s deceased sister (Supplemental Figure 1); degra-
dation of the DNA extracted from the same sample did not permit 
amplification and sequencing of the A201V mutation. The P224L 
mutation is reported 5 times in the Exome Aggregation Consortium 
(ExAC) database (allelic frequency of 4.4 × 10–5) with no homozy-
gous cases. The A201V mutation is present at an allelic frequency of 
0.002515 with no homozygotes. Likewise, within the Baylor-Hop-
kins Center for Mendelian Genomics database of over 6,000 
exomes, no homozygous or compound heterozygous cases of IRF8 
variants are found (23). Both mutations map to exon 7, in the region 
of IRF8 known as the IRF association domain (Figure 1C).
Figure 2. NK cell functional 
deficiency specifically occurs in 
IRF8 compound-heterozygous 
patient and is stable over time. 
NK cell cytotoxicity was evaluated 
by standard 51Cr release assay 
against K562 targets. (A) Shown 
is a representative assay includ-
ing our proband (A201V/P224L), 
his healthy brother (A201V/WT), 
and his healthy son (P224L/WT). 
The gray filled area represents the 
range of 10 healthy donors.  
***P < 0.0001, Student’s 
unpaired t test against mean 
of all healthy donors. Patient 
data are representative of 6 
independent repeats. (B) The 
proband’s NKD is stable over 
time as assessed by 51Cr release 
assay against K562 targets. 
Shown is relative specific lysis by 
patient NK cells at the highest 
effector-to-target ratio (dashed 
line, circles) compared with 
corresponding healthy donor 
control (solid line, squares) at 
dates from 2004 to 2012 (x axis). 
(C) 51Cr release assay of unrelated 
A201V/WT (daughter of proband 
or unrelated as indicated), P224L/
WT (son of proband), G139S/
WT, A179V/WT, and T96M/WT 
patients (circles). The gray filled 
area represents the range of 10 
normal donors. Each condition 
was performed in triplicate and 
is shown as the mean. (D) 51Cr 
release assay of freshly isolated 
purified patient (circles) and 
healthy donor (squares) NK cells 
against K562 target cells. Shown 
is 1 representative of 2 inde-
pendent experiments with each 
condition performed in triplicate.
Downloaded from http://www.jci.org on December  1, 2016.   https://doi.org/10.1172/JCI86276
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5jci.org
Figure 3. Stable impairment in NK cell terminal differentiation in patients with biallelic IRF8 mutations. NK cell phenotype was evaluated by multi-
parametric FACS phenotyping. (A) Representative FACS plot of healthy donor control (WT/WT) and our proband (A201V/P224L). Lymphocytes were gated 
on FSC/SSC. Data shown are representative of 6 independent repeats. (B) Stable NKD (left) and increased CD56bright population (right) in our proband 
shown over time (dashed line) with healthy donor shown as reference (solid line) at multiple dates from 2004 to 2015 (x axis). Single time point analysis 
of A201V/WT (unrelated, open diamond), A179V/WT (open triangle), an unrelated R83C/R291Q compound-heterozygous patient (solid inverted trian-
gle), and a K108E/K108E patient (solid diamond) is also shown. (C) Percentage of CD56+CD3− NK cells within the lymphocyte gate is shown for 4 normal 
controls, our proband at 4 independent time points, 3 unrelated heterozygous IRF8 mutation patients, an unrelated compound-heterozygous patient, and 
a K108E/K108E patient. (D) Percentage of CD56bright NK cells within the NK cell compartment is shown for the cohort described in C. (E) FACS phenotyping 
of heterozygous, compound-heterozygous, and homozygous IRF8 patients. For intracellular staining, mononuclear cells were stimulated (S) with PMA 
and ionomycin in the presence of brefeldin A or incubated without stimulation (U) before fixation, permeabilization, and detection of intracellular effector 
molecules. (F) Expression of IFN-γ (after PMA/ionomycin stimulation) and perforin and CD16 in unstimulated NK cells from patients and healthy donors 
gated on CD56dim and CD56bright subsets. Shown is mean ± SD of 3 independent experiments for perforin and CD16 in healthy donor and A201V/P224L 
patient; a single experiment is shown for the K108E/K108E patient and IFN-γ detection from all subjects. *P < 0.05 by unpaired Student’s t test. (G) Cyto-
kine secretion from healthy donor (HD) or A201V/P224L patient (Pt) detected by cytokine bead array from PBMCs stimulated for 4 hours by nonautologous 
EBV-transformed B cells in lytic cycle.
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ing flow cytometry. In the absence of stimulation, IRF8 was detect-
ed in both the cytoplasm and the nucleus of patient and control B 
cell lines. This was also observed for healthy donor NK cells, with 
colocalization between DAPI and IRF8 as calculated by similarity 
score (24) of 3.4 for patient cells, 2.2 for control B cells, and 2.2 for 
primary human NK cells (median values) (Figure 1F). Stimulation 
with IL-15 did not increase localization of IRF8 in primary human 
NK cells (similarity score 2.2, not shown). Together these data con-
firm novel compound heterozygous mutations in IRF8 that do not 
abrogate protein expression or nuclear localization.
Biallelic IRF8 mutation leads to impaired NK cell cytotoxic func-
tion. To specifically test the effect of biallelic mutations on NK 
cell cytotoxicity, we performed standard 51Cr release assays. As 
previously described, the proband has consistently low NK cell 
functional activity against the prototypical K562 target (ref. 1 and 
Figure 2A). The proband’s cytotoxic function was evaluated mul-
tiple times during a 10-year time interval and consistently showed 
profoundly decreased activity relative to normal controls with 
specific lysis (at maximal effector-to-target ratio) that was 0% and 
31% of normal control levels (Figure 2B). The patient’s children, 
carriers of the P224L or A201V mutations, had slightly decreased 
but normal cytotoxic function, as did his nephew and mother (Fig-
ure 2, A and C, and not shown). Unrelated carriers of the A201V 
mutation from a separate family of a different nationality similarly 
had normal NK cell cytotoxic function (Figure 2C), despite having 
late onset of pulmonary nontuberculous mycobacterial disease 
(Table 1). Other heterozygous patients (G139S/
WT, A179/WT, T96M/WT) also had normal 
NK cell function despite the presence of pulmo-
nary nontuberculous mycobacterial infection 
(Figure 2C and Table 1). To determine wheth-
er decreased NK cell lytic function in the pro-
band was due to low NK cell frequency within 
the lymphocyte population, cytotoxicity assays 
using purified NK cells were performed, and 
showed significantly decreased lysis of targets 
(Figure 2D), suggesting that an intrinsic defect 
in NK cell cytotoxic function underlies the stably 
decreased impairment observed. Therefore, the 
compound heterozygous A201V/P224L muta-
tion results in low/absent NK cell cytotoxic func-
tion, an effect that is repeatedly observed over 
extended time and likely accounts for the pro-
band’s profound susceptibility to viral disease.
Biallelic IRF8 mutation results in decreased 
NK cell number and impaired NK cell terminal dif-
ferentiation. We next functionally examined NK 
cells from probands with 2 different combinations of compound 
heterozygous and a homozygous (i.e., biallelic) variant allele: 
A201V/P224L, R83C/R291Q, and homozygous K108E. Human 
NK cells in peripheral blood fall largely within 2 dominant subsets 
with unique phenotypic and functional signatures. High density of 
CD56 and the presence of CD94/NKG2A, CD117, and CD62L on 
the cell surface classify the CD56bright subset phenotypically. These 
cells are considered the most potent cytokine producers upon 
stimulation, primarily of TNF-α and IFN-γ. The CD56dim subset 
is characterized by markers of terminal differentiation such as 
CD57, activating and inhibitory KIRs, and CD16, and is thought to 
be derived from the CD56bright subset (13). In addition, CD56dim NK 
cells express large quantities of perforin and granzymes; they are 
specialized for contact-mediated target cell lysis.
Consistently over the time of evaluation (>10 years) the 
patient had decreased frequency and absolute number of 
CD56+CD3− NK cells within the lymphocyte population (1.7%–
6.0% vs. 4.6%–13.7% in healthy controls) (Figure 3, A–C, and 
Table 1). Evaluation of the phenotypic subsets within peripher-
al blood showed a relative paucity of the CD56dim subset in the 
patient, accompanied by an overrepresentation of the CD56bright 
subset. From our initial evaluation in 2004 and at all subsequent 
times evaluated, patient 1’s CD56bright subset was between 30% 
and 40% (27.9%–40.3%) of the NK cell population, in contrast 
to controls, which fell within the previously described range 
(4.1%–8.4%) (Figure 3, A–C, and ref. 25). Evaluation of hetero-
Figure 4. Irf8–/– mice have a block in terminal NK cell 
maturation. Spleen and blood from Irf8–/–, Irf8+/– lit-
termates, and Irf8+/+ controls were analyzed by flow 
cytometry for markers of NK cell differentiation. (A) 
Representative FACS of spleen (top) and blood (bot-
tom) from the same mouse. Cells were gated on single 
cells, then NK1.1+CD3−. (B) Pooled spleen and blood 
from 4–6 mice per condition are shown. Data shown 
are mean ± SD. *P < 0.05 by Student’s unpaired t test.
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zygous A201V/WT subjects (both unrelated and related) showed 
normal frequencies of both NK cells within the peripheral blood 
mononuclear cell (PBMC) population (13.9%) and CD56bright NK 
cells (3.7%). Further, evaluation of other heterozygous individu-
als (T96M/WT, G139S/WT, A179V/WT) showed frequencies of 
NK cells and CD56bright NK cells consistent with normal controls 
(Figure 3, B–D). In contrast, the R83C/R291Q and the homozy-
gous K108E patient had low overall numbers of NK cells (3.9% 
and 5.4%, respectively) and a significantly expanded CD56bright 
population consistent with our proband (65.8% and 72.7%; Fig-
ure 3, B–D). Therefore, compound heterozygous or homozygous 
mutations in IRF8 selectively result in aberrant generation of the 
terminally mature subsets of NK cells and a decreased frequency 
of NK cells within the lymphocyte population.
Because of the patient’s consistently low NK cell cytotoxic 
function and abnormal NK cell subset distribution, we performed 
multiparametric flow cytometric immune phenotyping of NK cell 
subsets, including intracellular cytokines IFN-γ and TNF-α as well 
as perforin and granzymes. We evaluated the patient, his clinical-
ly unaffected single-heterozygous family members, an unrelated 
heterozygous A201V/WT patient with pulmonary nontuberculous 
mycobacterial infection, a heterozygous T96M/WT patient, an 
unrelated compound-heterozygous patient (R83C/R291Q), and a 
homozygous K108E patient (Table 1).
Multiparametric flow cytometric analysis of the proband’s 
lymphocytes showed that NK cell markers were consistent with 
the expanded CD56bright subset but otherwise showed no aber-
rant expression of markers of activation, inhibition, or granzyme 
B (Figure 3E). Despite decreased representation of the CD56dim 
subset, markers of NK cell terminal differentiation and memo-
ry (CD57, NKG2C) were expressed, as were activating receptors 
(NKG2D) and inhibitory receptors (NKG2A). Interestingly, how-
ever, our proband had consistently low levels of perforin at multi-
ple time points tested, as did the homozygous K108E patient (Fig-
ure 3E). Upon stimulation, the proband, as well as those patients 
with compound heterozygous variants in IRF8, expressed normal 
or higher than normal levels of IFN-γ and TNF-α measured both 
as percentage of the population expressing cytokine and on a per-
cell basis (Figure 3E and not shown). The production of IFN-γ 
was comparable between patient and control CD56bright NK cells, 
which are generally the most potent producers of IFN; however, 
the patient CD56dim NK cells had increased IFN-γ production rela-
tive to control. This accounted for the increase in IFN-γ production 
in his NK cells when considered as a total population (Figure 3F). 
The patient with K108E/K108E mutations had impaired IFN-γ 
production upon stimulation from both NK cell subsets, poten-
tially underscoring the different effects of the different mutations 
on immune function even in the context of similar NK cell pheno-
type. The observed decrease in perforin expression in our patient 
with A201V/P224L mutations and the patient with homozygous 
K108E mutations was confined to the CD56dim subset, the prima-
ry cytolytic effectors. CD16 (FcγRIIIA) was expressed at normal 
levels on CD56bright and CD56dim NK cells from the patients with 
A201V/P224L and R83C/R291Q mutations (Figure 3, E and F). 
Low expression of CD16 on NK cells from the K108E patient was 
restricted to the CD56dim NK cell subset (Figure 3F).
Given the important role that cytokine production plays in the 
control of the viral immune response and previously described 
DC deficiency in patients with IRF8 mutations, we sought to 
determine whether cytokine production in the context of costim-
ulation by accessory cells was impaired in our patient. To do so, 
we incubated PBMCs from healthy donor or patient with a non-
autologous EBV-transformed B cell line that had been induced 
to lytic cycle. Secreted cytokines (IL-12p40, IFN-γ, TNF-α, and 
IL-10) were measured by flow cytometric bead array. As suggest-
ed by the intracellular flow cytometry data, the coculture-induced 
production of IFN-γ and TNF-α was not impaired in the patient, 
and, similarly to that observed in cytokine-stimulated NK cells, 
Figure 5. Impairment in terminal NK cell differentiation is NK cell intrin-
sic. CD34+ hematopoietic stem cells were sorted from the proband and a 
healthy control, and NK cells were generated by coculture with OP9-DL1 
stromal cells for 35 days. Cells were harvested and analyzed in parallel with 
freshly isolated PBMCs from the proband or the same healthy donor. (A) In 
vitro–generated NK cells from healthy donor (left, WT/WT) or our proband 
(right, A201V/P224L) were analyzed by FACS for CD56 expression and 
CD16 (top) and CD94 (bottom) expression. (B) Histogram showing mean 
fluorescence intensity of CD56 expression on in vitro–derived NK cells from 
healthy donor (gray histogram) or patient 1 (empty histogram).
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numbers of these subsets (blood 0.45 × 106 ± 0.4 × 106, spleen 3.6 
× 106 ± 1.9 × 106) when compared with wild-type controls (blood 
0.36 × 106 ± 0.5 × 106, spleen 0.31 × 106 ± 0.3 × 106). Conversely, 
Irf8–/– mice had decreased frequency of mature Mac-1hiCD27lo NK 
cells (48.3% ± 3.9%) compared with wild-type controls (64.3% ± 
3.9%). This was despite increased absolute cell number (blood 1 × 
106 ± 0.6 × 106, spleen 5.7 × 106 ± 2.1 × 106) compared with controls 
(blood 0.7 × 106 ± 0.5 × 106, spleen 1.4 × 106 ± 0.6 × 106). Together, 
these demonstrate impairment in terminal maturation in mice with 
homozygous, but not heterozygous, Irf8 loss-of-function muta-
tions, suggesting an important parallel to our patients with biallelic 
IRF8 mutations and increased frequency of immature NK cells.
IRF8 is required for human NK cell development in a cell-intrinsic 
manner. Given the broad expression of IRF8 within immune cell 
populations, we sought to determine whether the observed effect 
on NK cell function was due to NK cell–intrinsic mechanisms or 
representative of the need for other immune or nonimmune cell 
types in NK cell development. Thus, we evaluated the ability of 
patient CD34+ hematopoietic stem cells (HSCs) to generate NK 
cells in isolation. HSCs were sorted from our proband’s peripheral 
blood and incubated on OP9-DL1 stromal cells for 28 days in the 
presence of IL-7, FLT3L, c-Kit, and IL-15, as this in vitro experi-
mental system has been previously demonstrated to promote 
NK cell development (14, 30, 31). As shown in Figure 5A, patient 
NK cells derived from CD34+ HSCs were largely CD56bright (76% 
vs. 19.7% from healthy donor control). The mean fluorescence 
intensity of CD56 was significantly higher on patient cells ver-
sus the normal control (224 vs. 112 in healthy donor) (Figure 5B), 
consistent with immaturity and incomplete maturation. In addi-
tion, while healthy donor–derived cells acquired CD16 (58%), the 
patient-derived cells had decreased CD16 expression yet retained 
CD94, a phenotype that is reflective of an immature state. These 
results show that the role for IRF8 is cell intrinsic and that IRF8 is 
functioning directly in the generation of appropriate and mature 
NK cell subsets during development.
IRF8 is expressed in human NK cell subsets and is upregulated 
upon IL-15 stimulation. Expression of IRF8 in human NK cell devel-
opmental subsets has not been previously determined. We per-
formed real-time PCR and intracellular flow cytometry to evaluate 
the expression of IRF8 in human NK cell developmental subsets. 
While human peripheral blood contains only the CD56bright and 
CD56dim NK cell subsets, we used human tonsil as a source of devel-
oping NK cells and evaluated these cells based on known markers 
the production of IFN-γ in these cocultures was increased (Figure 
3G). Interestingly, elevated secretion of both IL-12 and IL-10 was 
also observed from patient cells.
As IRF8 serves a previously identified role in DC develop-
ment and IRF8 deficiency has been shown to lead to a variable 
loss or absence of DC subsets, we performed phenotypic analy-
sis of monocyte and DC populations. A subtle deficiency of plas-
macytoid dendritic cell (pDCs) and CD141+ DCs was observed in 
the index patient relative to heterozygous family members and 
a wild-type control (Supplemental Figure 2). These differences 
were within the scope of those previously ascribed to human IRF8 
mutations and were not as severe as those observed in the patient 
with homozygous K108E mutation (19).
Our findings, however, suggested a novel NK cell phenotype 
of arrested terminal maturation in the presence of biallelic IRF8 
mutations. To further determine the role of IRF8 in NK cell mat-
uration, we performed phenotypic analysis of NK cells from Irf8–/–, 
Irf8+/–, and Irf8+/+ mice by flow cytometry. While murine NK cells 
do not express CD56, and not all transcription factor functions are 
evolutionarily conserved between human and murine NK cells, 
the developmental stages of murine NK cells can be stratified 
according to expression of CD27 and CD11b (Mac-1) (26). As pre-
viously reported (27–29), Irf8–/– mice had significant splenomegaly 
and lymphocytosis, leading to increased absolute NK cell number 
in both spleen (14 × 106 ± 5.7 × 106) and blood (1.2 × 106 ± 0.7 × 
106) relative to that of Irf8+/+ controls (spleen 2.5 × 106 ± 1.2 × 106, 
blood 0.89 × 106 ± 0.6 × 106). Despite this, as seen in Figure 4, NK 
cells from blood and spleen of Irf8–/–, but not Irf8+/–, mice had an 
increased frequency of immature Mac-1loCD27hi NK cells (22.5% 
± 2.7%) within the NK cell population when compared with wild-
type controls (9.7% ± 1.8%). This was also reflected by absolute 
Figure 6. IRF8 is expressed in all NK cell developmental subsets and is 
upregulated upon IL-15 stimulation. (A) NK cell developmental subsets 
were isolated from tonsil as described in Methods, and IRF8 was detected 
by intracellular flow cytometry. Shown is 1 representative experiment from 
3 independent experiments from 3 normal donors. FMO, fluorescence 
minus one; PB, peripheral blood. (B) NK cells were incubated for 6 hours 
with 10 ng/ml of IL-15 or vehicle control, and then RNA was extracted and 
qPCR performed as described in Methods. ***P < 0.001 by Student’s t 
test. Shown are the means of 3 independent experiments performed on 
3 donors, each done in quadruplicate. (C) NK cells were stimulated as in 
B and subjected to flow cytometric analysis as in A. Dashed line, IL-15 stim-
ulated; solid line dark histogram, unstimulated; solid line light histogram 
unstained. (D) Shown is the mean ± SD of 3 independent experiments.  
*P < 0.05 by unpaired Student’s t test. MFI, mean fluorescence intensity.
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developmental subsets isolated from tonsil, as well as those from 
peripheral blood, expressed significant quantities of IRF8. Further, 
stimulation of primary human NK cells with IL-15 for as few as 6 
hours resulted in an upregulation of IRF8 as measured by quanti-
of differentiation (stages 1–5) (32). As shown in Figure 6A, healthy 
human donors expressed IRF8 in all developmental subsets as 
measured by intracellular flow cytometry. Interestingly, expres-
sion was highest in stage 1 (CD34+) NK cell precursors; however, all 
Figure 7. Deregulation of multiple genes in A201V/P224L IRF8 patient NK cells. (A) Promoter assays were performed in HeLa cells with WT or mutant 
alleles as indicated. Mutant and WT IRF8 showed indistinguishable regulation of PU.1- and IRF1-dependent genes. Results are displayed as fold increase 
relative to cells cotransfected with the empty vector. These data are derived from triplicate samples and are displayed as the mean ± SD. Data were 
analyzed using Student’s unpaired t test (**P < 0.01, ***P < 0.001). (B) Selected NK cell genes up- or downregulated in IRF8 A201V/P224L patient and 
heterozygous family members identified by NanoString gene expression analysis. (C) Selected immune genes classified by Ingenuity Pathway Analysis 
that are up- or downregulated more than 3-fold in the A201V/P224L patient relative to all 3 healthy donors (total NK cells). (D) Expression of selected 
genes validated by qPCR of B cell lines from 2 healthy donors (HD), patient (Pt), or patient cells stably transfected with WT IRF8 (Pt+IRF8). Mean ± SD of 
1 representative experiment of 4 (performed in quadruplicate) is shown normalized to the mean of HD. *P < 0.05, ***P < 0.0001 by ordinary 1-way ANOVA 
with Tukey’s multiple comparisons.
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Discussion
Genetic causes of aberrations in NK cell development are exceed-
ingly rare but confer familial susceptibility to disease, particularly 
viral infection. Here we identify a novel human NK cell develop-
mental defect and cause of NKD due to biallelic mutation in the 
IRF8 gene. Interestingly, while homozygous and heterozygous 
IRF8 mutations lead to a spectrum of DC deficiency ranging from 
mild to severe, biallelic variants in our patient and 2 additional 
unrelated patients result in NKD as a result of a block in terminal 
maturation. In our patient this phenotype occurs in the context 
of normal activation of PU.1 and IRF1, underscoring the varying 
impact of IRF8 mutations.
Our proband was originally diagnosed in 1980 and reported 
in 1982 with the first case of non–X-linked susceptibility to EBV as 
a result of NKD (1), and as such is within the first reported cohort 
of patients with NKD. Having the unique opportunity to study 
the 1 surviving affected patient from this family longitudinally 
has underscored the stability of the NK cell phenotype, namely 
decreased NK cell number with a paucity of CD56dim NK cells and 
interrupted maturation.
The IRF family plays a well-documented role in inflamma-
tion, and these transcription factors are also becoming increasing-
ly recognized for their importance in hematopoietic development 
(35, 36). In particular, a critical requirement for IRF8 in DC devel-
opment is described in mice with both hypomorphic and knock-
out mutations of IRF8, as well as previously described patients 
with heterozygous and homozygous mutations (19). Patients 
with homozygous K108E mutation are close in phenotype to the 
knockout mouse, with severe deficits of monocytes and DCs 
and a myeloproliferative disorder (29, 37–39). This homozygous 
mutation in the DNA-binding domain of IRF8 abrogates nucle-
ar translocation but not protein expression, leading to impaired 
function and defective IL-12, IFN-γ, and TNF-α production (21). 
In contrast, the spontaneous heterozygous T80A mutation leads 
to specific loss of the CD1c+ compartment of CD11c+ DCs but 
retention of CD141+ DCs, monocytes, and CD123+ plasmacyt-
oid DCs (19). Relative to disease caused by autosomal recessive 
K108E mutation, the T80A heterozygous mutation leads to a 
less severe clinical course. IL-12 production, but not type I IFN, 
is affected. In both cases, both B and T cell numbers are largely 
normal; however, CD25hiFoxP3+ Treg numbers are decreased in 
patients with K108E mutation (39).
The mechanism for the differential impact of IRF8 mutations 
on DC and NK cell homeostasis remains unclear. Gene dosage 
and mutation site–specific effects are commonly observed in 
transcriptions factors such as IRF8 that are regulated by superen-
hancer structures (40). As opposed to A201V/P224L, the K108E 
mutation is unable to activate IRF1- and PU.1-dependent tran-
scription and, in the biallelic state, is associated with monocyte 
and DC deficiency and a very marked distortion of NK cell devel-
opment in the ratio of CD56bright to CD56dim cells. The patient 
described here with A201V/P224L mutation has an NK pheno-
type with only subtle DC deficiency, in keeping with the ability 
of the 2 variants to activate transcription with PU.1 and IRF1. As 
these processes are required for DC development and function, 
these data suggest that additional IRF8-dependent mechanisms 
are required for normal NK cell homeostasis.
tative PCR (qPCR) (3-fold; Figure 6B) and flow cytometry (1.3-fold; 
Figure 6, C and D). Therefore, IRF8 is expressed in human NK cells 
and is responsive to IL-15 stimulation. This observation is consis-
tent with a critical role for IRF8 during NK cell development.
IRF8 is required for NK cell expression of transcription factors 
and NK cell effector molecules. Previously reported homozygous 
K108E mutations in IRF8 lead to impaired synthesis of IL-12 due 
to abrogated IRF1-dependent transcription of the IL12B gene 
(19). To determine whether the mutations in our proband affect-
ed functional binding of IRF8 with cofactors IRF1 and PU.1, we 
performed luciferase assays with each allelic variant (WT, A201V, 
and P224L). As seen in Figure 7A, neither of our patient’s vari-
ants affected transcriptional activity dependent on PU.1 or IRF1. 
This is consistent with the observation that DC development was 
only partially affected in the patient and contrasts with biallelic 
K108E mutation, in which transactivation with IRF1 was severely 
impaired and monocytes and DCs were absent (19). Collective-
ly, this underscores the variability of mutational impact on the 
DC phenotype. To determine the effect that the IRF8 mutations 
have on human NK cell function, we performed NanoString gene 
expression analysis (Human Immunology v2 gene set) on isolat-
ed NK cells from our proband, his family members, and 3 healthy 
donor controls. We identified 403 genes with a greater than 1.5-
fold up- or downregulation in the patient relative to all 3 healthy 
donors (Supplemental Table 2). These included 18 of particular 
relevance to NK cell development, cytotoxicity, or homeostasis 
(Figure 7B), including transcription factors NFIL3, IKZF2, TBX21, 
EOMES, and STAT5A/B. Differentially expressed effector mol-
ecules and cell surface receptors included PRF1, GZMA, GZMB, 
CCR7, CD27, CD2, HAVCR2, and KLRG1. Ingenuity Pathway 
Analysis of all genes differentially up- or downregulated more 
than 5-fold revealed transcription factors, growth factors, kinases, 
and transmembrane receptors (Figure 7C). To provide additional 
evidence that the genes differentially expressed in NK cells might 
be direct transcriptional targets of the mutant IRF8 proteins, we 
compared genes that consistently had an absolute fold change 
of ≥2 with published ChIP sequencing data (33). This analysis 
revealed a significant overlap of differentially expressed genes 
with loci associated with 1 or more IRF8 peaks (Supplemental 
Table 3). There was no preferential association of up- or downreg-
ulated transcripts with the presence of IRF8 binding. To further 
biologically validate differential expression of potential direct 
targets, we focused on NFIL3 and PRDM1, where IRF8 binding 
was observed in the study by Langlais et al. (33) (Supplemental 
Table 3), and IRF4, which also has evidence of IRF8 binding by 
ChIP sequencing (34). We performed qPCR on healthy donor– or 
patient-derived B cell lines and found decreased expression of 
each in the patient relative to 3 healthy donors (Figure 7D). Re- 
expression of WT IRF8 protein in the patient B cell line rescued 
the expression of IRF4 and PRDM1 and partially rescued expres-
sion of NFIL3. Therefore, biallelic IRF8 deficiency results in 
decreased expression of human NK cell transcriptional regulators 
and effector molecules as well as genes not previously associated 
with NK cell regulation. Complementation of the patient B cell 
line with WT IRF8 restores expression of these, demonstrating a 
direct effect of compound heterozygous A201V/P224L mutations 
on the expected IRF8-mediated gene expression profile.
Downloaded from http://www.jci.org on December  1, 2016.   https://doi.org/10.1172/JCI86276
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 1jci.org
and the significant downregulation of JAK3 and STAT5A and -B in 
our patient relative to 3 healthy donors supports this hypothesis.
While we show that the NK cell developmental defect is intrin-
sic, an additional model for the requirement of IRF8 in NK cell 
development and function would be through the trans-presen-
tation of IL-15 by DCs, which would potentially make the loss of 
DCs and functional defect of NK cells in IRF8 patients particularly 
damaging. Our data support a link between IL-15, IRF8, and NK 
cell development, as we show that IL-15 increases IRF8 protein 
expression in as few as 6 hours in ex vivo NK cells. This observation 
suggests a need for the IL-15–induced proliferation of CD56bright 
NK cells in the generation of the CD56dim subset, as proposed in 
the report of MCM4 deficiency, the only other reported immune 
deficiency to result in this distinctive NK cell phenotype (2). This 
concept was originally proposed by Lutz et al. after they showed 
that CD56bright NK cells undergo significantly greater proliferation 
than the CD56dim subset (48). In addition, FLT3L-mediated devel-
opment of DCs is dependent on IRF8 signaling, and FLT3L-defi-
cient mice have decreased NK cell number and impaired NK cell 
development (49). Therefore, our data could suggest a similar 
requirement for IRF8 in FLT3L-mediated signaling in NK cells.
While a direct role for IRF8 in NK cell development has not 
been described, IRF2-deficient mice have reduced NK cell num-
ber and, as a result, impaired NK cell cytotoxic function (50, 51). 
Further, IRF2-deficient bone marrow is enriched for immature 
NK cells (selective loss of the CD11bhiDX5hi subset) with higher 
rates of apoptosis and decreased sensitivity to IL-15, a defect that 
is cell intrinsic (51). Whether the loss of CD56dim NK cells in IRF8 
deficiency is a result of accelerated apoptosis of this subset, as is 
the case for IRF2 mice, or a result of impairment in the transition 
from CD56bright to CD56dim, remains to be seen. While IRF1-defi-
cient mice also have decreased NK cell number and function, IRF1 
is required for IL-15 production by bone marrow stromal cells, and 
the NKD in these mice is due to the loss of IL-15 in the niche (52).
IRF8 plays a role in lineage commitment, particularly of DCs 
and B cells, and can substitute for the highly related factor IRF4 
in some circumstances (18, 40, 53, 54). Both IRF4 and IRF8 have 
the capacity to act as either transcriptional activators or repressors 
but require other lineage-specific transcription factors as binding 
partners to achieve the appropriate outcome. For example, IRF4/
IRF8 can interact with PU.1 or SPI-B at cis-regulatory regions 
termed Ets-IRF composite elements (EICEs) in B cells, DCs, and 
macrophages. While PU.1 is not required for NK cell development, 
PU.1-deficient NK cells in mice showed reduced proliferation both 
at baseline and in response to IL-12 and IL-2 (55). However, PU.1 
is difficult to detect in mature NK cells and is hypothesized to be 
required exclusively for lineage commitment (56). While EICEs 
are fairly well characterized, genetic approaches in T cells and 
DCs have recently revealed novel motifs recognized by IRF4/
IRF8, such as AP-1–IRF composite elements bound by BATF-IRF 
complexes (57, 58). Given the normal regulation of PU.1 and IRF1 
elements by our patient’s IRF8 variants, work is currently under-
way to identify novel binding partners of IRF8 in NK cells.
Recent high-resolution analysis of the ontology of both mouse 
and human ILC and NK cell lineages shows IRF8 highly expressed 
specifically in NK cells and, in the case of human cells, intraep-
ithelial ILC1s (59, 60). Our gene expression analysis of purified 
While all of our patient’s surviving single-heterozygous fam-
ily members have unremarkable medical history, an unrelated 
patient with heterozygous A201V/WT mutation of IRF8 and 
late-onset pulmonary nontuberculous mycobacterial infection 
was identified, although a role for this IRF8 change in her disease 
state is unclear. The late onset of disease in an unrelated patient 
with A201V mutation suggests the relatively mild impact of this 
variant and that careful monitoring of heretofore clinically unaf-
fected heterozygous family members may be prudent.
The apparent requirement for IRF8 in an NK cell–intrinsic 
manner, as we show using in vitro differentiation experiments, 
points to a direct role in the generation of appropriately distrib-
uted CD56bright and CD56dim NK cells and the subsequent acquisi-
tion of effector function. As with GATA2 mutations, it is intriguing 
that perturbation of development that allows for the presence of 
CD56dim NK cells in peripheral blood nevertheless significantly 
affects the function of these cells. The profound disease in our 
patient and the consistent absence of NK cell cytotoxic function 
as a result of this developmental block speak to the strict regula-
tion of this process and support a model in which CD56bright cells 
are the precursors of CD56dim. The impaired terminal maturation 
of NK cells from Irf8–/–, but not Irf8+/–, mice suggests a conserved 
requirement for IRF8 in the final stages of NK cell development 
and supports a linear relationship between the subsets. As with 
GATA2 mutations, CD56+CD3+ T cells are present in our patient, 
often at higher frequencies than in normal controls.
IRF8 is known to play a role in both cell fate decision and func-
tional control of viral infection. IRFs are well-described down-
stream mediators of TLR signaling, and IRF8 mediates TLR9 sig-
naling through TRAF6 and NF-κB (41, 42). Production of IFN-γ and 
TNF-α was normal in our patient in NK cells stimulated by PMA/
ionomycin or EBV-transformed B cells, suggesting that disruption 
of cytokine production was not the primary mechanism of viral 
susceptibility in our patient. Elevated levels of IFN-γ (both intracel-
lular and secreted in response to stimuli) were measured from our 
patient at multiple times of assessment. While the clinical signifi-
cance of this is unclear, it may be related to PRDM1 downregulation 
(detected by gene expression array and qPCR of patient B cell lines), 
as PRDM1 has been previously shown to directly bind and negative-
ly regulate the IFN-γ locus in human NK cells (43). In contrast, as 
previously reported in PBMCs (19), K108E/K108E NK cells did not 
produce IFN-γ in response to stimulation, suggesting that the dif-
ferential effect of the mutations on IRF1 activation may include dif-
fering effects on IFN-γ production in NK cells. In primary NK cells 
or NK-92 cell lines, cytokine stimulation increases levels of nucle-
ar IRF8 and increased binding to DNA (43, 44). In CD8+ T cells, 
common γ chain signaling in combination with CD3 cross-linking 
results in increased IRF8 expression in concert with JAK/STAT 
signaling and leads to differentiation of CD8+ effectors from naive 
precursors. Deletion of IRF8 results in decreased, but not absent, T 
lymphocyte cytotoxicity, and it is hypothesized that presentation of 
γc cytokine, namely IL-15, in combination with antigen by neigh-
boring DCs could drive CD8+ differentiation (45). IL-15 is unique 
among cytokines in its absolute requirement for NK cell develop-
ment and homeostasis in both mice and humans (46, 47). There-
fore, the positioning of IRF8 in this critical signaling pathway speaks 
to its importance in generating mature, functional human NK cells, 
Downloaded from http://www.jci.org on December  1, 2016.   https://doi.org/10.1172/JCI86276
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 2 jci.org
sity centrifugation. Human K562 target cells were used for 51Cr release 
assays and maintained in supplemented RPMI media as previously 
described (72). K562 cells were acquired from American Type Culture 
Collection and routinely confirmed to be mycoplasma negative.
Murine NK cell phenotyping. Irf8–/– mice were generated as described 
previously (29) and were a gift from Keiko Ozato (NIH, Bethesda, Mary-
land, USA). Male and female mice between 9 and 12 weeks of age were 
euthanized upon arrival in accordance with Baylor College of Medi-
cine’s animal care guidelines. Spleens were removed and single-cell 
suspensions prepared by mechanical separation and density centrifuga-
tion as previously described (73). Blood was obtained by heart puncture 
immediately following euthanasia. All cells were maintained in PBS/2% 
FCS at 4°C throughout the staining procedure. Cells were stained for 
viability with LIVE/DEAD cell staining kit according to the manufac-
turer’s instructions (Thermo Fisher). Rat anti-mouse Fc Block (Becton 
Dickinson) was added for 10 minutes on ice, and then fluorophore-con-
jugated specific antibodies against extracellular markers were added 
for 30 minutes (antibodies listed in Supplemental Table 4). Cells were 
washed once in 2% FCS/PBS, then fixed in a final concentration of 1% 
paraformaldehyde. Cells were acquired and data analyzed as described 
for human flow cytometry and immune phenotyping.
Generation of lymphoblastoid cell lines. Lymphoblastoid cell lines 
were generated from patient PBMCs by addition of EBV supernatant 
as previously described (74). Briefly, PBMCs were transduced with a 
B95-8 EBV supernatant and cultured in RPMI medium with 10% FBS, 
2 mM glutamine, and 1 μg/ml cyclosporin A. Cell lines were confirmed 
mycoplasma negative before their use in experiments.
NK cell functional assays. Standard 51Cr release assays were per-
formed in round-bottomed plates against K562 target cells as pre-
viously described (75).
Flow cytometry and immune phenotyping. Fluorophore-conjugat-
ed antibodies used for multiparametric flow cytometry analysis of 
patient PBMCs are listed in Supplemental Table 4. Where indicated, 
stimulation for the detection of intracellular cytokines was by PMA/
ionomycin for 4 hours in the presence of brefeldin A followed by fixa-
tion and permeabilization with BD Cytofix/Cytoperm. For intracellu-
lar staining of IRF8 by flow cytometry, cells were permeabilized using 
the FoxP3 transcription buffer staining kit (eBioscience) followed by 
incubation with IRF8 eFluor 710 (clone V3GYWCH, eBioscience). 
Flow cytometry was acquired on a BD Fortessa configured for 14 col-
ors. All analysis was done in FlowJo X (Tree Star). Positive populations 
were identified as those with fluorescence greater than that of isotype 
or fluorescence-minus-one controls. Cytokine bead arrays were per-
formed with custom BD Biosciences CBA Flex Sets using IL-12, IFN-γ, 
TNF-α, and IL-10 probes. PBMCs (2 × 106) were incubated for 4 hours 
with 105 EBV-transformed B cells previously induced to lytic cycle 
with 200 ng/ml phorbol 12-myristate 13-acetate. Data were analyzed 
with FlowJo X (Tree Star), and statistical analysis was performed and 
graphed using Prism 6.0 software (GraphPad Software).
Imaging flow cytometry. Cells were fixed and permeabilized using 
FoxP3 transcription buffer (eBioscience) followed by incubation with 
IRF8 eFluor 710 (clone V3GYWCH, eBioscience) and DAPI. Samples 
were acquired on an ImageStream MkII (EMD Millipore) with a ×40 
objective. Spectral compensation was applied using single-stained 
controls. Images were processed and exported using IDEAS software 
(EMD Millipore). Similarity score was calculated in IDEAS as a mea-
sure of colocalization.
NK cells suggests that IRF8 plays a direct role in the regulation of 
NK cell genes required for maturation and function of human NK 
cells. These include NFIL3 (encoding E4BP4), PRDM1 (encod-
ing BLIMP-1), TBX21 (encoding T-bet), and IKZF2 (encoding 
HELIOS), all previously shown to be required for mature NK cell 
generation and/or homeostasis (43, 61–66). E4bp4–/– mice fail to 
generate even immature NK cell precursors, indicating a very ear-
ly blockade in development, and E4BP4 is considered a master 
regulator of NK cell fate (61, 64, 65). The previously demonstrat-
ed gene dosage effect of E4BP4 suggests that repression but not 
absence of NFIL3, as seen in our patient, may lead to decreased 
mature NK cell numbers while not completely abrogating devel-
opment (61), and placing NFIL3 downstream of IRF8 would be 
consistent with previous reports showing normal IRF8 expression 
in Nfil3–/– mice (67). Similarly, Tbx21–/– mice fail to generate mature 
NK cells and T-bet expression increases with NK cell maturation, 
with T-bet highly expressed in the CD56dim NK cell subset (62, 68). 
Both PRDM1 and HELIOS tune NK cell responsiveness; PRDM1 
is a transcriptional repressor that binds directly to TNF and IFNG 
loci to regulate cytokine secretion in human NK cells (43) and is 
bound directly by IRF8 in B cells and macrophages (34), where-
as HELIOS regulation is a mechanism of modulation of NK cell 
activity mediated through NKp46 ligation (69). Finally, the NK 
cell defect observed in our patient may be attributable to the sig-
nificant downregulation of STAT5a and STAT5b, in concert with 
JAK3 and perforin. This signaling axis has been shown to be crit-
ical for NK cell survival and function, and STAT5b regulates NK 
cell cytolytic activity by binding directly to the perforin promoter 
(70, 71). Collectively, our data suggest that IRF8 may be playing a 
role in both NK cell lineage commitment and effector responses, 
which is in keeping with the functional and developmental defects 
observed in NK cells from patients with biallelic IRF8 mutations.
In summary, we have defined a novel NKD and primary 
immunodeficiency that occurs specifically as a result of biallelic 
mutations in IRF8 encoding the transcription factor IRF8. These 
alterations result in impaired NK cell function, decreased NK 
cell number, and loss of the CD56dim subset of human NK cells, 
reflecting impaired NK cell terminal maturation also observed in 
Irf8–/–, but not Irf8+/–, mice. Immunodeficiency occurring in asso-
ciation with IRF8 mutation is likely to involve defects of NK cells 
in addition to previously described loss of monocytes, DCs, and 
macrophage function. These findings define a novel, critical role 
for IRF8 function in NK cell development, extending the previous-
ly described range of phenotypes associated with IRF8 mutation 
in humans and identifying IRF8 mutation as the fourth genetic 
explanation for classical NKD leading to aberrant NK cell devel-
opment and association with susceptibility to viral disease.
Methods
Human NK cell preparation and target cell lines. PBMCs were isolated by 
density centrifugation over Ficoll-Paque lymphocyte isolation medi-
um according to the manufacturer’s protocol (Amersham). For enrich-
ment of NK cells for qPCR analysis, whole blood was incubated with 
RosetteSep (STEMCELL Technologies) before density centrifugation. 
For isolation of cells from tonsils, tissue was obtained from routine 
tonsillectomies and mechanically separated by passing through a 
40-μm strainer prior to isolation of secondary lymphoid cells by den-
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was done using the mean of 8 negative control probes. Normalization 
was performed by calculation of the geometric mean of positive con-
trols and content normalization parameters (15 housekeeping genes). 
Data processing was performed using nSolver software, and data were 
exported to Ingenuity Pathway Analysis for further analyses. Genes 
up- and downregulated greater than 1.5-fold in samples relative to the 
mean of all 3 healthy donor controls were considered significant.
Luciferase assays. Constructs encoding WT human IRF8 or allelic 
variants A201V and P224L were generated in the pIRES2-EGFP expres-
sion vector (Clontech). These were cotransfected with vectors encoding 
IRF1 or PU.1 and reporter luciferase vectors harboring interferon-stim-
ulated response element (ISRE) or EICE motifs and quantified using the 
Promega dual luciferase assay system. Details of the PSMB8 and TAPA-
SIN promoter luciferase vectors have been described previously (76).
Statistics. Statistical analysis was performed using Prism 6.0 (Graph-
Pad Software). Unpaired 2-tailed Student’s t test was used to compare 
data sets. Ordinary 1-way ANOVA with Tukey’s multiple comparisons 
test was performed for multiple comparisons. For all data shown, error 
bars denote SD. A P value less than 0.05 was considered significant.
Study approval. All studies were performed in accordance with the 
Declaration of Helsinki with the written and informed consent of all 
participants under the guidance of Children’s Hospital of Philadelphia, 
NIH, University of Newcastle, and Baylor College of Medicine Institu-
tional Review Boards. Animal studies were performed in accordance 
with the Baylor College of Medicine and NIH Animal Care Committees.
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Western blotting. Lymphoblastoid cell lines (3 × 105) from patient 
or healthy donor were lysed, separated by 4%–10% SDS-PAGE gel, 
then transferred to nitrocellulose membrane, and blocked with skim 
milk. IRF8 was detected with anti-ICSBP (clone C-19, Santa Cruz Bio-
technology) and actin with anti-actin (catalog A2066, Sigma-Aldrich) 
followed by goat anti-rabbit IRDye 700 secondary antibody. Proteins 
were detected on a LiCor Odyssey.
Quantitative reverse transcriptase PCR. RNA was extracted from 
enriched NK cells or secondary lymphoid cells (SLC) using DirectZol 
(Genesee Scientific) or RNeasy (Qiagen), and cDNA was made using 
VILO (Invitrogen). IRF8, PRDM1, NFIL3, and IRF4 were amplified on 
a Roche Light Cycler by Taqman gene expression array. GAPDH was 
used to normalize expression for each sample. Each condition was 
performed in quadruplicate. Analysis was performed with Roche Light 
Cycler software and exported to Excel before graphing with Prism 6.0 
(GraphPad software).
Genetic analyses. Genomic DNA was extracted from EDTA-pre-
served nonheparinized blood samples using the Gentra PureGene 
Blood Kit (Qiagen). Whole exome sequencing was conducted as pre-
viously described (23). Briefly, exonic portions of genomic DNA frag-
ments were captured in solution using custom VCrome probes (Nim-
bleGen). Resulting DNA was sequenced using Illumina HiSeq 2500 
equipment. Data processing and variant annotation were performed 
per standard pipeline analyses. Variants were evaluated using both 
recessive and dominant models. Bioinformatic filters were placed 
using a minor allelic frequency less than 0.005 in recessive mod-
els within the Baylor-Hopkins Center for Mendelian Genomics (18), 
ESP5400, 1000 Genomes, and ExAC databases. Potential recessive 
variants were also excluded if present in the ExAC database with a 
homozygote or hemizygote count of 10 or greater. For compound het-
erozygous analyses, variants were excluded if both variants were pres-
ent in the maternal exome or in the exome of the unaffected brother. 
For autosomal dominant model analyses, variants were excluded with 
minor allelic frequencies greater than 0.001 in the same databases 
and if present in the ExAC database with an allele count greater than 
5. Variants were confirmed by Sanger sequencing; primers were con-
structed using Primer3 (http://biotools.umassmed.edu/bioapps/
primer3_www.cgi), and amplified DNA constructs were sequenced by 
the Baylor DNA Sequencing Core Facility. Sequences were visualized 
using 4Peaks software (Nucleobytes). For the deceased sister, forma-
lin-fixed paraffin-embedded gallbladder tissue slices were retrieved 
from the Pathology Department at the University of Pennsylvania 
(Philadelphia, Pennsylvania, USA). DNA was extracted by the Baylor 
Human Genome Sequencing Center for Sanger sequencing.
In vitro NK cell differentiation. CD34+ precursors were isolated 
from peripheral blood of the patient or healthy donor and highly puri-
fied by fluorescence-based cell sorting. Following purification, cells 
were incubated on mitotically inactivated OP9-DL1 stromal cells (a 
gift from J.C. Zúñiga-Pflücker, University of Toronto, Toronto, Ontar-
io, Canada) in media containing 5 ng/ml IL-3, 20 ng/ml IL-7, 10 ng/ml 
FLT3L, and 10 ng/ml IL-15 for 4 weeks. After culture, cells were phe-
notyped by FACS in parallel with control cells from a healthy donor.
RNA isolation and gene expression analysis. NK cells were isolated 
by FACS sorting to greater than 95% purity following enrichment by 
RosetteSep negative selection (STEMCELL Technologies). Fifty to a 
hundred nanograms of RNA was analyzed with the Human Immunol-
ogy v2 probe set using a NanoString nCounter. Background correction 
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